Chengyu Zou

Dr. Chengyu Zou


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2026 in Cell
Verified
Journal Article
Closed access
CZChengyu Zou
Chengyu Zou
PLPeiying Li
Peiying Li
BLBin Li
Bin Li
TSTim Sparwasser
Tim Sparwasser
JYJunying Yuan
Junying Yuan

7 November 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
QWQiaoyan Wu
Qiaoyan Wu
CZChengyu Zou
Chengyu Zou
Microglial dysfunction is a major contributor to the pathogenesis of multiple neurodegenerative diseases. The neurotoxicity of microglia associated with oxidative stress largely depends on NF-κB pathway activation, which promotes the production and release of microglial proinflammatory cytokines and chemokines. In this review, we discuss the current literature on the essential role of the NF-κB pathway on microglial activation that exacerbates neurodegeneration, with a particular focus on RIPK1 kinase activity-dependent microglial dysfunction. As upregulated RIPK1 kinase activity is associated with reactive oxygen species (ROS) accumulation in neurodegenerative diseases, we also discuss the current knowledge about the mechanistic links between RIPK1 activation and ROS generation. Given RIPK1 kinase activity and oxidative stress are closely regulated with each other in a vicious cycle, future studies are required to be conducted to fully understand how RIPK1 and ROS collude together to disturb microglial homeostasis that drives neurodegenerative pathogenesis.

3 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
XCXiaoshi Chen
Xiaoshi Chen
SLSixuan Li
Sixuan Li
ANAntonia Neubauer
Antonia Neubauer
XLXiang Li
Xiang Li
WMWei Mao
Wei Mao
CZChengyu Zou
Chengyu Zou
The combination of brain glucose hypometabolism and hyperphosphorylated Tau (p-Tau) pathology is the strongest known clinical predictor of imminent cognitive decline, yet how these factors cooperate to drive dementia remains unknown. Here, we show that glucose hypometabolism synergizes with p-Tau to trigger neuronal loss through necroptosis. Under low-glucose conditions, accumulated p-Tau forms a molecular scaffold that directly recruits the necroptotic kinase RIPK1, while concomitant loss of the necroptosis checkpoint protein A20 removes a critical brake on this death pathway. This dual mechanism thereby precipitates neuronal necroptosis independent of classical TNF/TNFR1 signaling paradigm. Restoring A20 expression with acetyl-L-carnitine as a dietary supplement or preventing the p-Tau – RIPK1 interaction using a RIPK1 derived competitive peptide alleviates neuronal necroptosis and brain atrophy in a Tau transgenic mouse model. Collectively, our findings uncover a previously unrecognized metabolism-driven necroptotic signaling cascade initiated by a p-Tau-RIPK1 hub, providing mechanical insight into how glucose hypometabolism synergizes with p-Tau to drive neurodegeneration.

5 October 2026 in Neuroscience Bulletin
Verified
Journal Article
Closed access
PDF file
XCXiaoshi Chen
Xiaoshi Chen
CZChengyu Zou
Chengyu Zou